Guanlin Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guanlin Xiao has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Yangxue Li
Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine/Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, 510095, China
11 shared publicationsJieyi Jiang
Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine/Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, 510095, China
10 shared publicationsZhihao Zeng
Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine/Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, 510095, China
10 shared publicationsGuanlin Xiao
Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine/Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, 510095, China
8 shared publicationsSumei Li
Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine/Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, People’s Republic of China
8 shared publicationsAili Xu
Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine/Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, 510095, China
7 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-25
Screening and Determination of Biomarkers and Their Associated Active Components for Enhanced Therapeutic Effect of Exocarpium Citri Grandis–Folium Ginkgo Couplet on Liver Injury Caused by Hyperlipidemia via UPLC-TOF-MS and UPLC-MS
Introduction: The combination of Exocarpium Citri Grandis–Folium Ginkgo (E–GC) demonstrates superior therapeutic effects on liver injury caused by hyperlipidemia compared with individual use; however, accurate and quantifiable indicators for evaluating the efficacy and quality of the couplet remain lacking. Reliance solely on changes in certain differential metabolites or the bioavailability of chemical components is insufficient to confirm the superior efficacy of the couplet. Methods: In this study, a rat model of liver injury caused by hyperlipidemia was used to verify the enhanced efficacy of E-GC. Subsequently, network pharmacology combined with molecular biology validation was applied to identify the primary regulatory targets. The results were integrated with UPLC-TOF-MS, UPLC-MS and database analyses to identify biomarkers indicating the enhanced efficacy of E-GC, as well as serum concentrations of active components in E-GC to quantitatively evaluate the effect of the couplet on their bioavailability. Finally, correlation statistical analyses were conducted on the above-mentioned data to confirm that the identified biomarkers and significantly altered active components can characterize the enhanced efficacy of the couplet. Results: Metabolomics analysis identified 59 related metabolites, among which arachidonic acid, choline, deoxycholic acid, N-acetylserotonin, and cholic acid significantly increased in the liver following E-GC treatment, with similar changes observed in serum levels (p< 0.05). A total of 36 components were identified, apigenin, naringin, and ginkgolide A/B/C exhibited significantly increased bioavailability after combination (p< 0.05). These changes were closely associated with the improved regulation of PXR-FXR expression by E-GC compared with individual use, and E-GC also exerted strong regulatory effects on downstream targets, such as LXR, FGF1, ABCB1b, and ERK. Conclusion: Through the above analyses, in order to solve the problem of lacking accurate and quantifiable indexes to evaluate the effect of TCM couplet, a method was successfully established for evaluating the enhanced efficacy of E-GC in treating liver injury caused by hyperlipidemia, and the principal biomarkers and quality control indicators based on active components were identified.
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-25
Open AccessScreening and Determination of Biomarkers and Their Associated Active Components for Enhanced Therapeutic Effect of Exocarpium Citri Grandis–Folium Ginkgo Couplet on Liver Injury Caused by Hyperlipidemia via UPLC-TOF-MS and UPLC-MS
Introduction: The combination of Exocarpium Citri Grandis–Folium Ginkgo (E–GC) demonstrates superior therapeutic effects on liver injury caused by hyperlipidemia compared with individual use; however, accurate and quantifiable indicators for evaluating the efficacy and quality of the couplet remain lacking. Reliance solely on changes in certain differential metabolites or the bioavailability of chemical components is insufficient to confirm the superior efficacy of the couplet. Methods: In this study, a rat model of liver injury caused by hyperlipidemia was used to verify the enhanced efficacy of E-GC. Subsequently, network pharmacology combined with molecular biology validation was applied to identify the primary regulatory targets. The results were integrated with UPLC-TOF-MS, UPLC-MS and database analyses to identify biomarkers indicating the enhanced efficacy of E-GC, as well as serum concentrations of active components in E-GC to quantitatively evaluate the effect of the couplet on their bioavailability. Finally, correlation statistical analyses were conducted on the above-mentioned data to confirm that the identified biomarkers and significantly altered active components can characterize the enhanced efficacy of the couplet. Results: Metabolomics analysis identified 59 related metabolites, among which arachidonic acid, choline, deoxycholic acid, N-acetylserotonin, and cholic acid significantly increased in the liver following E-GC treatment, with similar changes observed in serum levels (p< 0.05). A total of 36 components were identified, apigenin, naringin, and ginkgolide A/B/C exhibited significantly increased bioavailability after combination (p< 0.05). These changes were closely associated with the improved regulation of PXR-FXR expression by E-GC compared with individual use, and E-GC also exerted strong regulatory effects on downstream targets, such as LXR, FGF1, ABCB1b, and ERK. Conclusion: Through the above analyses, in order to solve the problem of lacking accurate and quantifiable indexes to evaluate the effect of TCM couplet, a method was successfully established for evaluating the enhanced efficacy of E-GC in treating liver injury caused by hyperlipidemia, and the principal biomarkers and quality control indicators based on active components were identified.
- Open Access
- 26 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1349
Identification of Hypolipidemic Constituents from Microctis folium Using an Integrated Strategy of Chemical Profiling, Pharmacokinetics, Network Pharmacology and Experimental Validation
Background/Objective: Traditionally derived from the dried leaves of Microcos paniculata L., Microctis folium (M. folium) has been employed to manage various inflammatory and metabolic conditions. Despite its reported hypolipidemic potential, the active constituents contributing to this effect and their molecular mechanisms of action remain to be determined. Therefore, this study aimed to systematically identify the active hypolipidemic constituents of M. folium and elucidate their mechanisms of action through an integrated strategy combining chemical profiling, pharmacokinetic screening, network pharmacology, and experimental validation. Methods: UPLC fingerprint and UPLC-QQQ-MS/MS were employed to characterize and quantify the chemical constituents of M. folium. Pharmacokinetic analysis was conducted to identify systemically absorbed compounds. Network pharmacology was applied to predict potential targets and signaling pathways. The lipid-lowering effects were subsequently validated in vitro using an oleic acid/palmitic acid (OA/PA)-induced lipid accumulation model in HepG2 cells and in vivo in a Triton WR-1339-induced hyperlipidemia mouse model. Results: UPLC fingerprint analysis identified 15 common peaks among 21 batches of M. folium, with similarity values ranging from 0.885 to 0.990, indicating good chemical consistency. Eighteen representative compounds were quantified, among which flavone C-glycosides and phenolic acids were predominant. Pharmacokinetic results demonstrated that multiple M. folium’s constituents were absorbed into systemic circulation. Network pharmacology analysis identified 73 potential targets related to hyperlipidemia and highlighted the PI3K-Akt signaling pathway as a key regulatory pathway. In vitro experiments showed that M. folium’s compounds significantly reduced intracellular lipid accumulation and oxidative stress in OA/PA-induced HepG2 cells. Furthermore, in vivo studies demonstrated that vitexin, ferulic acid, isoferulic acid, and N-trans-feruloyltyramine significantly reduced serum and hepatic lipid levels, including TC, TG, and LDL-c, alleviated hepatic steatosis, and improved liver injury and oxidative stress markers in Triton WR-1339-induced hyperlipidemic mice. Conclusions: M. folium exerts significant lipid-lowering effects through multi-component and multi-target mechanisms involving regulation of lipid metabolism and oxidative stress, partly mediated by activation of the PI3K-Akt signaling pathway. These findings provide a scientific basis for the development of M. folium’s natural agents for the treatment of hyperlipidemia.
- 26 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1349
Open AccessIdentification of Hypolipidemic Constituents from Microctis folium Using an Integrated Strategy of Chemical Profiling, Pharmacokinetics, Network Pharmacology and Experimental Validation
Background/Objective: Traditionally derived from the dried leaves of Microcos paniculata L., Microctis folium (M. folium) has been employed to manage various inflammatory and metabolic conditions. Despite its reported hypolipidemic potential, the active constituents contributing to this effect and their molecular mechanisms of action remain to be determined. Therefore, this study aimed to systematically identify the active hypolipidemic constituents of M. folium and elucidate their mechanisms of action through an integrated strategy combining chemical profiling, pharmacokinetic screening, network pharmacology, and experimental validation. Methods: UPLC fingerprint and UPLC-QQQ-MS/MS were employed to characterize and quantify the chemical constituents of M. folium. Pharmacokinetic analysis was conducted to identify systemically absorbed compounds. Network pharmacology was applied to predict potential targets and signaling pathways. The lipid-lowering effects were subsequently validated in vitro using an oleic acid/palmitic acid (OA/PA)-induced lipid accumulation model in HepG2 cells and in vivo in a Triton WR-1339-induced hyperlipidemia mouse model. Results: UPLC fingerprint analysis identified 15 common peaks among 21 batches of M. folium, with similarity values ranging from 0.885 to 0.990, indicating good chemical consistency. Eighteen representative compounds were quantified, among which flavone C-glycosides and phenolic acids were predominant. Pharmacokinetic results demonstrated that multiple M. folium’s constituents were absorbed into systemic circulation. Network pharmacology analysis identified 73 potential targets related to hyperlipidemia and highlighted the PI3K-Akt signaling pathway as a key regulatory pathway. In vitro experiments showed that M. folium’s compounds significantly reduced intracellular lipid accumulation and oxidative stress in OA/PA-induced HepG2 cells. Furthermore, in vivo studies demonstrated that vitexin, ferulic acid, isoferulic acid, and N-trans-feruloyltyramine significantly reduced serum and hepatic lipid levels, including TC, TG, and LDL-c, alleviated hepatic steatosis, and improved liver injury and oxidative stress markers in Triton WR-1339-induced hyperlipidemic mice. Conclusions: M. folium exerts significant lipid-lowering effects through multi-component and multi-target mechanisms involving regulation of lipid metabolism and oxidative stress, partly mediated by activation of the PI3K-Akt signaling pathway. These findings provide a scientific basis for the development of M. folium’s natural agents for the treatment of hyperlipidemia.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 5973-5991
Mechanisms of Microctis Folium in Hyperlipidemia: Integrating Serum Pharmacochemistry, Network Pharmacology, and Transcriptomics
Background: Microctis Folium (MF), a traditional Chinese medicine (TCM), has shown promising effects in treating hyperlipidemia (HLP), yet its active constituents and mechanisms remain largely unclear. Purpose: This study aimed to systematically elucidate the lipid-lowering effects of MF on high-fat diet (HFD)-induced HLP and identify its pharmacodynamic material basis and molecular mechanism through an integrated multi-omics strategy. Methods: We developed a UPLC-QTOF-MS/MS method to identify the chemical constituents of MF and the compounds absorbed in rat serum after oral administration of MF. Network pharmacology, molecular docking, and experimental validation were utilized to explore the potential mechanism of MF for the treatment of HLP. Results: UPLC-QTOF-MS/MS identified 51 chemical compounds in MF and established their material basis. Analysis of serum samples after administration of MF identified 24 enriched compounds as potential active compounds and 597 corresponding prospective targets. Overlaying these compounds with 396 HLP-related genes revealed 101 potential core genes, mainly including AKT1, PTGS2, EGFR, mTOR, and NF-κB. Network pharmacology and transcriptomic analyses indicated that MF regulates key pathways in HLP, notably the PI3K/AKT, mTOR, and NF-κB pathways. Molecular docking further validated the binding affinities of MF key compounds (rutin and isovitexin) to AKT1, mTOR, and NF-κB. In vivo studies confirmed MF’s lipid-lowering effects of MF in alleviating HFD-induced lipid accumulation. Compared to the HFD group, MF treatment significantly reduced serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels while increasing high-density lipoprotein cholesterol (HDL-C) levels. Finally, in vivo experiments confirmed the pivotal role of these pathways in the therapeutic effects of MF on HLP. Conclusion: The comprehensive approach adopted in this study reveals the molecular mechanism of MF for the treatment of HFD-induced HLP, lays an important foundation for elucidating the pharmacological and material basis of the therapeutic effects of MF, and highlights the value of multi-omics integration in TCM research.
- 1 July 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 5973-5991
Open AccessMechanisms of Microctis Folium in Hyperlipidemia: Integrating Serum Pharmacochemistry, Network Pharmacology, and Transcriptomics
Background: Microctis Folium (MF), a traditional Chinese medicine (TCM), has shown promising effects in treating hyperlipidemia (HLP), yet its active constituents and mechanisms remain largely unclear. Purpose: This study aimed to systematically elucidate the lipid-lowering effects of MF on high-fat diet (HFD)-induced HLP and identify its pharmacodynamic material basis and molecular mechanism through an integrated multi-omics strategy. Methods: We developed a UPLC-QTOF-MS/MS method to identify the chemical constituents of MF and the compounds absorbed in rat serum after oral administration of MF. Network pharmacology, molecular docking, and experimental validation were utilized to explore the potential mechanism of MF for the treatment of HLP. Results: UPLC-QTOF-MS/MS identified 51 chemical compounds in MF and established their material basis. Analysis of serum samples after administration of MF identified 24 enriched compounds as potential active compounds and 597 corresponding prospective targets. Overlaying these compounds with 396 HLP-related genes revealed 101 potential core genes, mainly including AKT1, PTGS2, EGFR, mTOR, and NF-κB. Network pharmacology and transcriptomic analyses indicated that MF regulates key pathways in HLP, notably the PI3K/AKT, mTOR, and NF-κB pathways. Molecular docking further validated the binding affinities of MF key compounds (rutin and isovitexin) to AKT1, mTOR, and NF-κB. In vivo studies confirmed MF’s lipid-lowering effects of MF in alleviating HFD-induced lipid accumulation. Compared to the HFD group, MF treatment significantly reduced serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels while increasing high-density lipoprotein cholesterol (HDL-C) levels. Finally, in vivo experiments confirmed the pivotal role of these pathways in the therapeutic effects of MF on HLP. Conclusion: The comprehensive approach adopted in this study reveals the molecular mechanism of MF for the treatment of HFD-induced HLP, lays an important foundation for elucidating the pharmacological and material basis of the therapeutic effects of MF, and highlights the value of multi-omics integration in TCM research.
- Open Access
- 3 January 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1444967
Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia
BuShao Tiaozhi Capsule (BSTZC), a novel drug in China, has been used to treat hyperlipidemia (HLP) in clinical practice for many years. Despite our previous studies suggesting that BSTZC can treat HLP, there is a lack of a rapid and systematic method to explore its active components. Therefore, in this study, we aimed to investigate the active components and mechanisms of BSTZC in treating HLP by integrating serum pharmacology, pharmacokinetics, network analysis, and experimental validation. We first established UPLC fingerprints, calibrated 23 common peaks, and identified 13 common peaks, and the similarity was greater than 0.99 for 10 batches. A total of nine metabolites from BSTZC were identified in serum and considered as PK markers. The pharmacokinetic parameters of the PK markers were compared between the control group and the model group through the pharmacokinetics study to determine the dynamic changes of representative components in rats. Compared with the control group, the Cmax and AUC0→t of OXY, IVT, IVL, and KPF-3-G were significantly higher (P< 0.05); the AUC0→∞ of OXY, PN, and IVT was significantly higher (P< 0.05); and the t1/2 of IVT, SA, and KPF-3-G was significantly different (P< 0.05). In vivo experiments showed that BSTZC and its active components could effectively alleviate lipid metabolism disorders and liver injury, with obvious lipid-lowering effects. Further studies showed that BSTZC alleviated HLP by inhibiting the PI3K/Akt signaling pathway, which was consistent with the results of the network analysis study. Our results revealed the active components and mechanisms of BSTZC in the treatment of HLP, which could provide useful information to guide the clinical application of BSTZC.
- 3 January 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1444967
Open AccessIntegrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia
BuShao Tiaozhi Capsule (BSTZC), a novel drug in China, has been used to treat hyperlipidemia (HLP) in clinical practice for many years. Despite our previous studies suggesting that BSTZC can treat HLP, there is a lack of a rapid and systematic method to explore its active components. Therefore, in this study, we aimed to investigate the active components and mechanisms of BSTZC in treating HLP by integrating serum pharmacology, pharmacokinetics, network analysis, and experimental validation. We first established UPLC fingerprints, calibrated 23 common peaks, and identified 13 common peaks, and the similarity was greater than 0.99 for 10 batches. A total of nine metabolites from BSTZC were identified in serum and considered as PK markers. The pharmacokinetic parameters of the PK markers were compared between the control group and the model group through the pharmacokinetics study to determine the dynamic changes of representative components in rats. Compared with the control group, the Cmax and AUC0→t of OXY, IVT, IVL, and KPF-3-G were significantly higher (P< 0.05); the AUC0→∞ of OXY, PN, and IVT was significantly higher (P< 0.05); and the t1/2 of IVT, SA, and KPF-3-G was significantly different (P< 0.05). In vivo experiments showed that BSTZC and its active components could effectively alleviate lipid metabolism disorders and liver injury, with obvious lipid-lowering effects. Further studies showed that BSTZC alleviated HLP by inhibiting the PI3K/Akt signaling pathway, which was consistent with the results of the network analysis study. Our results revealed the active components and mechanisms of BSTZC in the treatment of HLP, which could provide useful information to guide the clinical application of BSTZC.
- Open Access
- 20 September 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1466114
Metabolomics and network pharmacology reveal partial insights into the hypolipidemic mechanisms of ferulic acid in a dyslipidemia mouse model
Introduction: Hyperlipidemia is a condition characterized by abnormal levels of lipids and lipoproteins in the plasma, posing significant health risks. Ferulic acid (FA) is an organic acid with therapeutic properties for diabetes and hyperlipidemia.Methods: To explore biomarkers for FA treatment of hyperlipidemia and elucidate the mechanisms of lipid-lowering-related changes in metabolic pathways by metabolomics and network pharmacology. Initially, a hyperlipidemic mouse model induced by triton WR-1339 was established to evaluate the therapeutic effects of FA. Subsequently, serum metabolomics was utilized to identify differential metabolites, and metabolic pathway analysis was performed using MetaboAnalyst 6.0. Thirdly, network pharmacology was employed to identify potential targets of FA for hyperlipidemia. Finally, the compound-target-metabolite (C-T-M) network obtained core targets and validated them with molecular docking.Results: Biochemical analysis and histological examination showed that FA had lipid-lowering effects on hyperlipidemic mice. It identified 31 potential biomarkers for FA against hyperlipidemia by metabolomics involving lipid and amino acid metabolism. Lipid and atherosclerosis signaling pathways were identified as the key signaling pathways of FA against hyperlipidemia by KEGG analysis. Conjoint analysis showed that FA against hyperlipidemia was associated with 18 core targets and six biomarkers. Molecular docking results showed that FA has a high binding affinity to these core targets.Discussion: Through the synergy of network pharmacology and metabolomics, this study provides insights into how FA regulates endogenous metabolites, underscoring its promise as a treatment for hyperlipidemia.
- 20 September 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1466114
Open AccessMetabolomics and network pharmacology reveal partial insights into the hypolipidemic mechanisms of ferulic acid in a dyslipidemia mouse model
Introduction: Hyperlipidemia is a condition characterized by abnormal levels of lipids and lipoproteins in the plasma, posing significant health risks. Ferulic acid (FA) is an organic acid with therapeutic properties for diabetes and hyperlipidemia.Methods: To explore biomarkers for FA treatment of hyperlipidemia and elucidate the mechanisms of lipid-lowering-related changes in metabolic pathways by metabolomics and network pharmacology. Initially, a hyperlipidemic mouse model induced by triton WR-1339 was established to evaluate the therapeutic effects of FA. Subsequently, serum metabolomics was utilized to identify differential metabolites, and metabolic pathway analysis was performed using MetaboAnalyst 6.0. Thirdly, network pharmacology was employed to identify potential targets of FA for hyperlipidemia. Finally, the compound-target-metabolite (C-T-M) network obtained core targets and validated them with molecular docking.Results: Biochemical analysis and histological examination showed that FA had lipid-lowering effects on hyperlipidemic mice. It identified 31 potential biomarkers for FA against hyperlipidemia by metabolomics involving lipid and amino acid metabolism. Lipid and atherosclerosis signaling pathways were identified as the key signaling pathways of FA against hyperlipidemia by KEGG analysis. Conjoint analysis showed that FA against hyperlipidemia was associated with 18 core targets and six biomarkers. Molecular docking results showed that FA has a high binding affinity to these core targets.Discussion: Through the synergy of network pharmacology and metabolomics, this study provides insights into how FA regulates endogenous metabolites, underscoring its promise as a treatment for hyperlipidemia.
- Open Access
- 10 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Anti-liver tumor ingredient exploration and validation of Elephantopus tomentosus Linn. by combining in silico and in vitro experiments
Elephantopus tomentosus (ET) Linn. was reported to be an anti-tumor plant. However, the chemical composition of ET and its anti-tumor compounds and potential mechanisms still unclear. In this paper, UPLC-Q-TOF–MS/MS was firstly used to identified the ingredients in ET and UPLC was used to determine the main compounds of ET. Network pharmacology was applied to predict the potential mechanisms of anti-liver cancer. Anti-tumor nuclear activate compounds and targets of ET were obtained and the anti-liver cancer effect was validated on HepG2. Finally, Molecule docking, RT-qPCR, and western blotting were used for verification of the relationship between nuclear activate compounds and nuclear targets and the potential anti-cancer mechanisms. The result showed that 42 compounds were identified in ET, which consisted of sesquiterpene lactones, flavonoids, and phenylpropanoid compounds. Scabertopin (ST), chlorogenic acid, Isochlorogenic acid B, Isochlorogenic acid A and Isochlorogenic acid C were identified as main compounds and were determined as 0.426%, 0.457%, 0.159%, 0.701%, and 0.103% respectively. 24 compounds showed high pharmacokinetics and good drug-likeness. 520 overlapping targets of the ET compounds and liver cancer were collected. The targets were used for KEGG and GO analysis. GO enrichment analysis suggested that the targets of 24 active compound closed related to promote apoptosis, inhibit proliferation, and regulate oxidative levels. KEGG enrichment analysis suggested that pathway in cancer was enriched most and p38 MAPK/p53 signaling pathway, which closely related to promoting apoptosis and inhibiting proliferation. Compounds-targets analysis based on the parameter of Betweenness, Closeness, Information, Eigenvector, Degree, and component content indicated that ST was the nucleus anti-tumor active compound of ET. HepG2 was first used to validated the anti-tumor effect of ST and the result showed that ST significantly inhibited HepG2 proliferation with a low IC50 less than 5 μM. Nucleus active compound targets, including TP53, CASP3, BCL2, EGFR, TNF-a, IL-1β, and IL-6 were enriched based on degree value of PPI analysis. Molecule docking suggested that ST showed a good combination to TGFBR1 with the combination energy less than − 5 kcal/mol. RT-qPCR result also suggested that ST significantly medicated the mRNA expression level of TP53, CASP3, BCL2, EGFR, TNF-a, IL-1β, and IL-6. Protein expression of p-p38/p38 and p-p53/p53 notable increased by ST treatment. In conclude, combining with UPLC-Q-TOF–MS/MS qualitative analysis, UPLC quantitative analysis, network pharmacology analysis, molecule docking, and in vitro experiments on HepG2, we suggest that ST is an anti-tumor ingredient of ET, which may target to TGFBR1 and promote apoptosis and inhibited proliferation of HepG2 by activating p38 MAPK/p53 signaling pathway. ST can be regarded as a quality marker of ET.
- 10 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Open AccessAnti-liver tumor ingredient exploration and validation of Elephantopus tomentosus Linn. by combining in silico and in vitro experiments
Elephantopus tomentosus (ET) Linn. was reported to be an anti-tumor plant. However, the chemical composition of ET and its anti-tumor compounds and potential mechanisms still unclear. In this paper, UPLC-Q-TOF–MS/MS was firstly used to identified the ingredients in ET and UPLC was used to determine the main compounds of ET. Network pharmacology was applied to predict the potential mechanisms of anti-liver cancer. Anti-tumor nuclear activate compounds and targets of ET were obtained and the anti-liver cancer effect was validated on HepG2. Finally, Molecule docking, RT-qPCR, and western blotting were used for verification of the relationship between nuclear activate compounds and nuclear targets and the potential anti-cancer mechanisms. The result showed that 42 compounds were identified in ET, which consisted of sesquiterpene lactones, flavonoids, and phenylpropanoid compounds. Scabertopin (ST), chlorogenic acid, Isochlorogenic acid B, Isochlorogenic acid A and Isochlorogenic acid C were identified as main compounds and were determined as 0.426%, 0.457%, 0.159%, 0.701%, and 0.103% respectively. 24 compounds showed high pharmacokinetics and good drug-likeness. 520 overlapping targets of the ET compounds and liver cancer were collected. The targets were used for KEGG and GO analysis. GO enrichment analysis suggested that the targets of 24 active compound closed related to promote apoptosis, inhibit proliferation, and regulate oxidative levels. KEGG enrichment analysis suggested that pathway in cancer was enriched most and p38 MAPK/p53 signaling pathway, which closely related to promoting apoptosis and inhibiting proliferation. Compounds-targets analysis based on the parameter of Betweenness, Closeness, Information, Eigenvector, Degree, and component content indicated that ST was the nucleus anti-tumor active compound of ET. HepG2 was first used to validated the anti-tumor effect of ST and the result showed that ST significantly inhibited HepG2 proliferation with a low IC50 less than 5 μM. Nucleus active compound targets, including TP53, CASP3, BCL2, EGFR, TNF-a, IL-1β, and IL-6 were enriched based on degree value of PPI analysis. Molecule docking suggested that ST showed a good combination to TGFBR1 with the combination energy less than − 5 kcal/mol. RT-qPCR result also suggested that ST significantly medicated the mRNA expression level of TP53, CASP3, BCL2, EGFR, TNF-a, IL-1β, and IL-6. Protein expression of p-p38/p38 and p-p53/p53 notable increased by ST treatment. In conclude, combining with UPLC-Q-TOF–MS/MS qualitative analysis, UPLC quantitative analysis, network pharmacology analysis, molecule docking, and in vitro experiments on HepG2, we suggest that ST is an anti-tumor ingredient of ET, which may target to TGFBR1 and promote apoptosis and inhibited proliferation of HepG2 by activating p38 MAPK/p53 signaling pathway. ST can be regarded as a quality marker of ET.
- 2 April 2024
- Published by Elsevier in Phytomedicine
- Vol. 132, 155545
ESL attenuates BLM-induced IPF in mice: Dual mediation of the TLR4/NF-κB and TGF-β1/PI3K/Akt/FOXO3a pathways
- 2 April 2024
- Published by Elsevier in Phytomedicine
- Vol. 132, 155545
ESL attenuates BLM-induced IPF in mice: Dual mediation of the TLR4/NF-κB and TGF-β1/PI3K/Akt/FOXO3a pathways